Valuation: Alzinova AB

Market Cap 208M 21.97M 19.01M 17.75M 16.31M 30.79M 2.09B 31.14M 81.67M 1.05B 82.51M 80.7M 3.49B P/E 2026 *
-3.81x
P/E 2027 * -2.71x
Enterprise Value 192M 20.28M 17.55M 16.39M 15.06M 28.43M 1.93B 28.75M 75.39M 966M 76.17M 74.5M 3.22B EV / Sales 2026 *
6.13x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day-1.34%
1 week-0.19%
Current month-11.38%
1 month+107.68%
3 months+134.44%
6 months+33.51%
Current year+24.00%
1 week 0.93
Extreme 0.93
1.23
1 month 0.48
Extreme 0.48
1.61
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%-0.19%-30.63%-69.63% 22.12M
+0.90%+0.21%-0.74%+13.87% 48B
+1.98%+7.31%+430.66%+532.17% 41.13B
+3.44%-2.84%+29.17%+8.81% 37.56B
+1.40%-0.89%+7.63%+61.93% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.16%-4.02% - - 16.12B
+2.20%+2.94%+35.92%+127.15% 16.05B
+1.25%+1.69%+4.72%+18.26% 13.76B
+4.25%-9.28%-0.78%-35.46% 12.1B
Average +1.63%-1.81%+54.54%+77.99% 25.05B
Weighted average by Cap. +1.91%-1.29%+85.85%+120.77%

Financials

2026 *2027 *
Net sales 31.35M 3.31M 2.86M 2.67M 2.46M 4.63M 314M 4.69M 12.29M 158M 12.42M 12.14M 526M -
Net income -3.2M -337K -292K -273K -251K -473K -32.1M -478K -1.25M -16.08M -1.27M -1.24M -53.66M -50.35M -5.31M -4.59M -4.29M -3.94M -7.44M -505M -7.53M -19.74M -253M -19.94M -19.5M -844M
Net Debt -16M -1.69M -1.46M -1.36M -1.25M -2.37M -160M -2.39M -6.27M -80.4M -6.34M -6.2M -268M -19M -2M -1.73M -1.62M -1.49M -2.81M -191M -2.84M -7.45M -95.47M -7.53M -7.36M -319M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
05/08/26 SEK 1.028 -1.34% 2,087,137
04/08/26 SEK 1.042 -4.93% 4,290,961
03/08/26 SEK 1.096 -5.52% 5,527,250
31/07/26 SEK 1.160 +14.17% 7,413,903
30/07/26 SEK 1.016 +3.89% 2,344,913

Annual profits - Rate of surprise